Skip to main content
Vaishali Pharma Limited logo

Vaishali Pharma Limited — Investor Relations & Filings

Ticker · VAISHALI ISIN · INE972X01022 LEI · 335800LHHVE3JLLKP681 National Stock Exchange of India Wholesale and retail trade
Filings indexed 428 across all filing types
Latest filing 2024-11-16 Regulatory Filings
Country IN India
Listing National Stock Exchange of India VAISHALI

About Vaishali Pharma Limited

https://www.vaishalipharma.com/

Vaishali Pharma Limited specializes in the sourcing, marketing, and distribution of a comprehensive range of healthcare products. The company’s portfolio encompasses Active Pharmaceutical Ingredients (APIs), finished formulations in various dosage forms such as tablets and injectables, and surgical supplies. It also provides veterinary products, herbal supplements, and nutraceuticals. The business model focuses on integrated supply chain management, facilitating the movement of medical products from manufacturing units to global markets. By adhering to international quality standards and leveraging an extensive distribution network, the company serves diverse therapeutic requirements. Its operations emphasize reliability in procurement and the delivery of cost-effective healthcare solutions to a global clientele across multiple regions, including Africa, Asia, and Latin America.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a notification addressed to the National Stock Exchange of India regarding the publication of un-audited financial results for the second quarter and half year ended 30th September 2024. It references Regulation 30 and Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which govern disclosure and publication of financial results. The document includes an advertisement published in newspapers and mentions that the Board of Directors approved these un-audited financial results. The content includes financial figures for the quarter and half year, but the document itself is a notice of publication and dissemination of these results rather than the full financial report. The document length is 15,000 characters, but the text is primarily an announcement of the results being published and available on stock exchange websites, not the full interim or quarterly report with detailed financial statements and analysis. Therefore, according to the MENU VS MEAL rule, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement of the publication of un-audited financial results, not the full interim report itself.
2024-11-16 English
Statement of deviation(s) or variation(s) under Reg. 32
Regulatory Filings Classification · 95% confidence The document is a statement submitted to the stock exchange (BSE Limited) regarding the deviation or variation in the utilization of funds raised by the company through issuance of equity shares by conversion of warrants. It references Regulation 32 of SEBI Listing Regulations and confirms no deviation or variation in the use of funds for the quarter ended September 30, 2024. The document includes a detailed statement reviewed by the Audit Committee and Board, but it is not a full financial report or earnings release. It is a regulatory compliance filing related to fund utilization disclosure. The document length is about 4830 characters, and it is a formal regulatory announcement rather than a full report or financial statement. Therefore, it fits best under Regulatory Filings (RNS) as a general compliance announcement that does not fit other specific categories like Capital/Financing Update or Earnings Release.
2024-11-14 English
Outcome of Board Meeting
Regulatory Filings
2024-11-14 English
Financial Result Updates
Regulatory Filings
2024-11-14 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2024-11-07 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a notification to the stock exchange about an upcoming Board Meeting scheduled to approve the Un-Audited Financial Results for the second quarter and half year ended 30th September 2024. It does not contain the financial results themselves but informs about the meeting where these results will be approved and subsequently sent. The document length is short (1689 characters) and it serves as an announcement rather than the actual financial report. According to the 'Menu vs Meal' rule, this is an announcement of a report, not the report itself. Therefore, it should be classified as a Regulatory Filing (RNS), which is the fallback category for such announcements that do not fit other specific categories.
2024-11-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.